Skip to main content

Intensive Care Units

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Coordination Pharmaceuticals
1 program
Automatic lateralization therapyN/A1 trial
Active Trials
NCT07087600Completed10Est. Oct 2025
MaaT Pharma
MaaT PharmaFrance - Lyon
1 program
fecal microbiota transferPHASE_21 trial
Active Trials
NCT03350178Terminated8Est. Feb 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
MaaT Pharmafecal microbiota transfer
Coordination PharmaceuticalsAutomatic lateralization therapy

Clinical Trials (2)

Total enrollment: 18 patients across 2 trials

NCT03350178MaaT Pharmafecal microbiota transfer

Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

Start: Jan 2018Est. completion: Feb 20198 patients
Phase 2Terminated
NCT07087600Coordination PharmaceuticalsAutomatic lateralization therapy

Immediate Effects of Automatic Lateralization in Critically Ill Patients

Start: Aug 2025Est. completion: Oct 202510 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.